


## Repinotan HCl

## Chemical Properties

CAS No. :	144980-77-8
Formula:	C <sub>21</sub> H <sub>25</sub> ClN <sub>2</sub> O <sub>4</sub> S
Molecular Weight:	436.95
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Repinotan HCl (Bay-x-3702) is an orally active, selective and potent 5-HT <sub>1A</sub> receptor agonist across the blood-brain barrier and is an aminomethylbenzidine derivative. Repinotan HCl has potent neuroprotective effects and can be used in studies of ischemic stroke and traumatic brain injury.
Targets(IC <sub>50</sub> )	5-HT Receptor

## Solubility Information

Solubility	DMSO: 80 mg/mL (183.09 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.55 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2886 mL	11.443 mL	22.8859 mL
5 mM	0.4577 mL	2.2886 mL	4.5772 mL
10 mM	0.2289 mL	1.1443 mL	2.2886 mL
50 mM	0.0458 mL	0.2289 mL	0.4577 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

A C Berends, et al. A review of the neuroprotective properties of the 5-HT<sub>1A</sub> receptor agonist repinotan HCl (BAYx3702) in ischemic stroke. *CNS Drug Rev.* Winter 2005;11(4):379-402.

Guenther U, Wrigge H, Theuerkauf N, Boettcher MF, Wensing G, Zinserling J, Putensen C, Hoeft A. Repinotan, a selective 5-HT<sub>1A</sub>-R-agonist, antagonizes morphine-induced ventilatory depression in anesthetized rats. *Anesth Analg.* 2010 Oct;111(4):901-7. doi: 10.1213/ANE.0b013e3181eac011. PubMed PMID: 20802053.

Teal P, Davis S, Hacke W, Kaste M, Lyden PD; Modified Randomized Exposure Controlled Trial Study Investigators., Fierus M; Bayer HealthCare AG.. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT). *Stroke.* 2009 Nov;40(11):3518-25. doi: 10.1161/STROKEAHA.109.551382. PubMed PMID: 19745176.

Heinig R, Sundaresan P, Shah A, Boettcher M. Effect of gender and age on the pharmacokinetics of repinotan. *Clin Drug Investig.* 2005;25(2):125-34. PubMed PMID: 17523762.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481